Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its... see more

Recent & Breaking News (NDAQ:AGEN)

Agenus to Present at the Jefferies 2015 Healthcare Conference

Business Wire May 28, 2015

Agenus Announces Closing of Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock

Business Wire May 27, 2015

Agenus Announces Pricing of Its Public Offering of Common Stock

Business Wire May 21, 2015

Agenus Announces Proposed Public Offering of Common Stock

Business Wire May 20, 2015

Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls

Business Wire May 14, 2015

An Opportunity in the Shifting Perceptions of the FDA

Accesswire May 13, 2015

Agenus to Host Research and Development Day on May 14, 2015

Business Wire May 8, 2015

NEJM Publishes Study Showing GSK's Shingles Vaccine Containing Agenus' QS-21 Stimulon® Adjuvant Provides over 97% Protection in People Over the Age of 50

Business Wire April 28, 2015

GSK's Malaria Vaccine Phase 3 Study Containing Agenus' QS-21 Published in The Lancet

Business Wire April 24, 2015

Agenus Reports First Quarter 2015 Financial Results

Business Wire April 23, 2015

Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform

Business Wire April 8, 2015

Agenus Reports Fourth Quarter and Full Year 2014 Financial Results

Business Wire February 26, 2015

Agenus to Present at the Cowen and Company 35th Annual Health Care Conference

Business Wire February 25, 2015

Agenus to Report Fourth Quarter and Year End 2014 Financial Results on February 26, 2015; Conference Call to Follow

Business Wire February 20, 2015

Agenus to Present at the 17th Annual BIO CEO & Investor Conference

Business Wire February 3, 2015

Agenus, Inc. - "2015: Poised To Be Another Transformative Year for Agenus"

Accesswire January 12, 2015

Agenus to Host Conference Call to Discuss Global Alliance with Incyte Corporation Today at 8:30 a.m. EST

Business Wire January 9, 2015

Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies

Business Wire January 9, 2015

Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant

GlobeNewswire December 18, 2014

Agenus Reports Third Quarter 2014 Financial Results

Business Wire October 31, 2014